Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
More than 60 countries and regions
The trial demonstrated a 20% reduction in the primary composite endpoint of cardiovascular death, nonfatal heart attack, or nonfatal stroke (hazard ratio 0.80, 95% CI 0.72-0.90)
(50 customer review) Aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos only placerat felis non aliquam.Mauris nec justo vitae ante auctor tol euismod sit amet Praesent commodo at massa eget suscipit
Nasal sprays may achieve similar pharmacokinetics to injections by avoiding first-pass metabolism, potentially matching Wegovy's efficacy with improved tolerability
Starting at low doses and gradual titration under medical supervision helps distinguish which medication causes any symptoms
